{
    "root": "352fc71c-7977-16a2-e063-6394a90a20ce",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clozapine",
    "value": "20250515",
    "ingredients": [
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "PEPPERMINT",
            "code": "V95R5KMY2B"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "CLOZAPINE",
            "code": "J60AR2IKIC"
        }
    ],
    "indications": "clozapine orally disintegrating tablets atypical antipsychotic indicated : treatment-resistant schizophrenia . efficacy established active-controlled study ( 1.1 , 14.1 ) . reducing suicidal behavior patients schizophrenia schizoaffective disorder . efficacy established active-controlled study ( 1.2 , 14.2 ) .",
    "contraindications": "starting dose : 12.5 mg daily twice daily ( 2.3 ) . cautious titration divided schedule ( 2.3 , 5.3 ) . titration : increase total daily increments 25 mg 50 mg per day , well-tolerated ( 2.3 ) . target dose : 300 mg 450 mg per day , divided doses , end 2 weeks ( 2.3 ) . subsequent increases : increase increments 100 mg less , twice weekly ( 2.3 ) . maximum daily dose : 900 mg ( 2.3 ) . tablets rapidly disintegrate placement mouth may chewed desired . water needed ( 2.2 ) .",
    "warningsAndPrecautions": null,
    "adverseReactions": "clozapine orally disintegrating tablets contraindicated patients history serious hypersensitivity clozapine ( e.g . , photosensitivity , vasculitis , erythema multiforme , stevens-johnson syndrome ) component clozapine orally disintegrating tablets [ ( 6.2 ) ] .",
    "indications_original": "Clozapine orally disintegrating tablets are an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study ( 1.1 , 14.1 ). Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study ( 1.2 , 14.2 ).",
    "contraindications_original": "Starting Dose: 12.5 mg once daily or twice daily ( 2.3 ). Use cautious titration and divided dosage schedule ( 2.3 , 5.3 ). Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated ( 2.3 ). Target Dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks ( 2.3 ). Subsequent Increases: increase in increments of 100 mg or less, once or twice weekly ( 2.3 ). Maximum Daily Dose: 900 mg ( 2.3 ). Tablets rapidly disintegrate after placement in the mouth and may be chewed if desired. No water is needed ( 2.2 ).",
    "adverseReactions_original": "Clozapine orally disintegrating tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine orally disintegrating tablets\n \n  [see\n  \n   Adverse Reactions (6.2)]\n \n  ."
}